SCHEMBL3503370

SCHEMBL3503370

O=C(Nc1ccc2ccccc2c1)c1ccc(C(=O)Nc2ccc3ccccc3c2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 16/20 0.84
RAB9A P51151 16/20 0.84
MEN1 O00255 9/20 0.84
KMT2A Q03164 9/20 0.84
TDP1 Q9NUW8 1/20 0.84
DEGS1 O15121 1/20 0.70
CASP3 P42574 4/20 0.69
SENP7 Q9BQF6 4/20 0.69
SENP6 Q9GZR1 2/20 0.69
KDM4E B2RXH2 2/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
SENP8 Q96LD8 1/20 0.69
NQO2 P16083 1/20 0.68
ALDH1A1 P00352 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MAPT P10636 1/20 0.62
F2 P00734 1/20 0.62
PLG P00747 1/20 0.62
PLAU P00749 1/20 0.62
KLKB1 P03952 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26885202 0.95 NPC1 (0.77) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL2229842 0.94 NPC1 (0.76) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL8081011 0.93 DEGS1 (0.82) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL3660083 0.93 NPC1 (0.74) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL2681024 0.92 NPC1 (1.00) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL2230642 0.92 NPC1 (0.77) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL8420152 0.92 NPC1 (0.72) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL26885214 0.90 DEGS1 (0.72) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL26885197 0.90 PTPN1 (0.73) NPC1RAB9AMEN1KMT2ATDP1
SCHEMBL7964170 0.89 RAB9A (0.73) NPC1RAB9AMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY THE WISTAR INSTITUTE (US) 2016-03-10 US disclosed
US-9234230-B2 Screening method and compounds for modulating telomerase activity THE WISTAR INSTITUTE (US) 2016-01-12 US disclosed
US-8377992-B2 TRBD-binding effectors and methods for using the same to modulate telomerase activity THE WISTAR INSTITUTE (US) 2013-02-19 US disclosed
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity THE WISTAR INSTITUTE (US) 2012-12-06 US disclosed
US-20100160260-A1 TRBD-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity THE WISTAR INSTITUTE 2010-06-24 US disclosed
US-5043399-A Blend of acetal resin and transparent polyamide elastomer ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1991-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309759-A1 Screening Method and Compounds for Modulating Telomerase Activity TERT, TERB1, TERF2 NPC1 3713/4885RAB9A 3522/4885MEN1 3807/4885
US-20160067257-A1 SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY TERT, TERB1, TERF2 NPC1 3713/4885RAB9A 3522/4885MEN1 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.